MyFinsight
Home
Blog
About
Contact
Download
Download image
Maturities of marketable
securities
$374,684K
Proceeds from securities
purchase agreement...
$50,000K
Proceeds from employee
stock purchase plan
$365K
Proceeds from exercise of
stock options
$42K
Sales of property and
equipment
$287K
Net cash provided by
investing activities
$54,097K
Net cash provided by
financing activities
$50,406K
Canceled cashflow
$320,874K
Canceled cashflow
$1K
Net (decrease)
increase in cash, cash...
-$45,521K
Canceled cashflow
$104,503K
Acquired ipr&d expense
$66,332K
Stock-based compensation
expense
$41,829K
Loss on securities
purchase agreement...
-$19,185K
Depreciation and
amortization expense
$11,539K
Loss on property and
equipment disposals, net
-$3,344K
Prepaid expenses, other
current assets and other...
-$2,823K
Impairment of long-lived
assets
$1,443K
Change in fair value of
success payment...
$831K
Loss (gain) on
marketable equity security
-$30K
Purchases of marketable
securities
$278,899K
Acquisition of assets, net of
cash acquired
$41,195K
Purchases of property and
equipment
$780K
Taxes paid related to
net share...
$1K
Net cash used in
operating activities
-$150,024K
Canceled cashflow
$147,356K
Net loss
-$274,448K
Accrued liabilities and
other current...
-$7,642K
Net amortization
and accretion on...
$4,959K
Non-cash lease income
$3,550K
Other non-current
liabilities
-$2,736K
Accounts payable
-$2,339K
Change in fair value of
contingent consideration...
$1,706K
Back
Back
Cash Flow
source: myfinsight.com
Lyell Immunopharma, Inc. (LYEL)
Lyell Immunopharma, Inc. (LYEL)